Positive start to fiscal 2008 for CardioDynamics as net loss narrows:
This article was originally published in Clinica
A 22% increase in sales helped impedance cardiology (ICG) firm CardioDynamics narrow its net loss for the first quarter of fiscal 2008. The San Diego, California-based company said the growth in revenues during the quarter (up from $4.7m in Q1 fiscal 2007 to $5.8m) was attributable to a three-fold increase in international sales and a 14% rise in sales of its BioZ non-invasive haemodynamic monitor. International sales improved after CardioDynamics fulfilled large customer orders from the Instituo de Salud del Estado de Mexico and an unnamed multi-hospital purchaser in eastern Europe. Net loss was approximately $1.5m, less 10% compared to the deficit of $1.6m during the same quarter in fiscal 2007.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.